Search

Your search keyword '"Scheffer, Peter G"' showing total 270 results
Start Over Author "Scheffer, Peter G"
270 results on '"Scheffer, Peter G"'

2. Perspectives of pregnant women on broadening the scope of noninvasive prenatal testing from screening for foetal aneuploidies to prediction of adverse pregnancy outcomes: A qualitative study

Author

MS Verloskunde, Klinisch Verloskundigen, Child Health, Circulatory Health, Becking, Ellis C., Henneman, Lidewij, Crombag, Neeltje M.T.H., Bertorotta, Janneke, Rijsbergen, Ylana, Bax, Caroline J., van Vliet-Lachotzki, Elsbeth, Scheffer, Peter G., Bekker, Mireille N., MS Verloskunde, Klinisch Verloskundigen, Child Health, Circulatory Health, Becking, Ellis C., Henneman, Lidewij, Crombag, Neeltje M.T.H., Bertorotta, Janneke, Rijsbergen, Ylana, Bax, Caroline J., van Vliet-Lachotzki, Elsbeth, Scheffer, Peter G., and Bekker, Mireille N.

Published
2024

3. Fetal fraction of cell-free DNA in noninvasive prenatal testing and adverse pregnancy outcomes: a nationwide retrospective cohort study of 56,110 pregnant women

Author

MS Verloskunde, Klinisch Verloskundigen, Epi Methoden Team 2, Cancer, JC onderzoeksprogramma Methodologie, Child Health, Circulatory Health, Becking, Ellis C, Scheffer, Peter G, Henrichs, Jens, Bax, Caroline J, Crombag, Neeltje M T H, Weiss, Marjan M, Macville, Merryn V E, Van Opstal, Diane, Boon, Elles M J, Sistermans, Erik A, Henneman, Lidewij, Schuit, Ewoud, Bekker, Mireille N, MS Verloskunde, Klinisch Verloskundigen, Epi Methoden Team 2, Cancer, JC onderzoeksprogramma Methodologie, Child Health, Circulatory Health, Becking, Ellis C, Scheffer, Peter G, Henrichs, Jens, Bax, Caroline J, Crombag, Neeltje M T H, Weiss, Marjan M, Macville, Merryn V E, Van Opstal, Diane, Boon, Elles M J, Sistermans, Erik A, Henneman, Lidewij, Schuit, Ewoud, and Bekker, Mireille N

Published
2024

4. Perspectives of pregnant women on broadening the scope of noninvasive prenatal testing from screening for foetal aneuploidies to prediction of adverse pregnancy outcomes: A qualitative study.

Author

Becking, Ellis C., Henneman, Lidewij, Crombag, Neeltje M. T. H., Bertorotta, Janneke, Rijsbergen, Ylana, Bax, Caroline J., van Vliet‐Lachotzki, Elsbeth, Scheffer, Peter G., and Bekker, Mireille N.

Abstract

Objective: To explore the perspectives of pregnant women on broadening the scope of noninvasive prenatal testing (NIPT) from screening for foetal aneuploidies to prediction of adverse pregnancy outcomes. Methods: Four online focus groups (n = 23 participants) and 14 individual semi‐structured interviews were conducted. Participants included pregnant women with and without a history of adverse pregnancy outcomes. Results: Both women at low and high risk of adverse pregnancy outcomes had a positive attitude towards using NIPT to predict adverse pregnancy outcomes. Perceived benefits included the possibility to potentially improve maternal and foetal outcomes by taking risk‐reducing measures and/or intensified monitoring during pregnancy and the ability to mentally prepare for the potential adverse outcome. Perceived concerns included anxiety and stress caused by a high‐risk test result, a false sense of control over pregnancy, and potential false reassurance. Additionally, women reasoned that broadening the scope of NIPT could increase the complexity of prenatal screening and raised concerns on the combined screening aims in one test (prediction of adverse pregnancy outcomes to improve foetal and maternal health vs. screening for foetal aneuploidies to increase reproductive autonomy). On a societal level, considerations on the risk of medicalising pregnancy and overall pressure to opt for NIPT were mentioned. Conclusion: In general, pregnant women have a positive attitude towards broadening the scope of NIPT to the prediction of pregnancy outcomes, although some concerns are acknowledged. Key points: What is already known about this topic? In the future, the scope of noninvasive prenatal testing (NIPT) could expand from screening for foetal aneuploidies to increase reproductive autonomy and the prediction of adverse pregnancy outcomes to improve foetal and maternal health.The perspectives of pregnant women on using NIPT to predict adverse pregnancy outcomes have not yet been explored. What does this study add? This study shows that pregnant women have a positive attitude towards expanding the scope of NIPT to the prediction of adverse pregnancy outcomes.Possibly improving health outcomes through risk‐reducing interventions is a main perceived benefit, while potential anxiety because of a high‐risk test result is a perceived concern.If the future scope of NIPT expands, policy makers should take into account the needs and concerns of pregnant women. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Exploring the role of oxidative stress and the effect of N‐acetylcysteine in thiopurine‐induced liver injury in inflammatory bowel disease: A randomized crossover pilot study.

Author

van Asseldonk, Dirk P., Crouwel, Femke, Seinen, Margien L., Scheffer, Peter G., Veldkamp, Agnes I., de Boer, Nanne K., Lissenberg‐Witte, Birgit, Peters, Godefridus J., and van Bodegraven, Adriaan A.

Subjects
INFLAMMATORY bowel diseases, OXIDATIVE stress, LIVER injuries, ACETYLCYSTEINE, XANTHINE oxidase, AMINE oxidase
Abstract

Thiopurine treatment is regularly complicated by drug‐induced liver injury. It has been suggested that oxidative stress may play a synergistic role. To assess whether thiopurine‐induced liver injury coincides with increased oxidative stress and whether co‐administration with N‐acetylcysteine is protective, we performed a randomized open label crossover pilot study in inflammatory bowel disease patients with thiopurine‐induced increased serum liver tests. The study comprised four stages of 4 weeks. Patients received no additional therapy followed by N‐acetylcysteine 1200 mg twice a day, or the other way around, alongside ongoing thiopurine treatment. The third and fourth stages comprised a washout period and thiopurine reintroduction period. Nine patients completed the study, and the addition of N‐acetylcysteine decreased myeloperoxidase concentrations (33.6–24.5 pmol/L, p = 0.038). The other biomarkers remained unchanged, including thiopurine metabolites, xanthine oxidase activity, thiopurine S‐methyltransferase activity and serum liver enzyme activity tests. Reintroduction of thiopurines led to an increase of F2‐isoprostanes (101–157 ng/mmol, p = 0.038), but not of serum liver enzyme activity tests. Results suggests that thiopurines may increase oxidative stress and although the addition of N‐acetylcysteine led to a decrease in plasma myeloperoxidase concentrations, it does not protect from thiopurine‐induced increase of serum liver tests. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Fetal fraction of cell-free DNA in non-invasive prenatal testing and adverse pregnancy outcomes: a nationwide retrospective cohort study of 56,110 pregnant women

Author

BECKING, Ellis C., primary, SCHEFFER, Peter G., additional, HENRICHS, Jens, additional, BAX, Caroline J., additional, CROMBAG, Neeltje MTH., additional, WEISS, Marjan M., additional, MACVILLE, Merryn VE., additional, van OPSTAL, Diane, additional, BOON, Elles MJ., additional, SISTERMANS, Erik A., additional, HENNEMAN, Lidewij, additional, SCHUIT, Ewoud, additional, and BEKKER, Mireille N., additional

Published
2023
Full Text
View/download PDF

10. Fetal fraction of cell-free DNA in noninvasive prenatal testing and adverse pregnancy outcomes:a nationwide retrospective cohort study of 56,110 pregnant women

Author

Becking, Ellis C., Scheffer, Peter G., Henrichs, Jens, Bax, Caroline J., Crombag, Neeltje M.T.H., Weiss, Marjan M., Macville, Merryn V.E., Van Opstal, Diane, Boon, Elles M.J., Sistermans, Erik A., Henneman, Lidewij, Schuit, Ewoud, Bekker, Mireille N., Becking, Ellis C., Scheffer, Peter G., Henrichs, Jens, Bax, Caroline J., Crombag, Neeltje M.T.H., Weiss, Marjan M., Macville, Merryn V.E., Van Opstal, Diane, Boon, Elles M.J., Sistermans, Erik A., Henneman, Lidewij, Schuit, Ewoud, and Bekker, Mireille N.

Abstract

Background: Noninvasive prenatal testing by cell-free DNA analysis is offered to pregnant women worldwide to screen for fetal aneuploidies. In noninvasive prenatal testing, the fetal fraction of cell-free DNA in the maternal circulation is measured as a quality control parameter. Given that fetal cell-free DNA originates from the placenta, the fetal fraction might also reflect placental health and maternal pregnancy adaptation. Objective: This study aimed to assess the association between the fetal fraction and adverse pregnancy outcomes. Study Design: We performed a retrospective cohort study of women with singleton pregnancies opting for noninvasive prenatal testing between June 2018 and June 2019 within the Dutch nationwide implementation study (Trial by Dutch Laboratories for Evaluation of Non-Invasive Prenatal Testing [TRIDENT]-2). Multivariable logistic regression analysis was used to assess associations between fetal fraction and adverse pregnancy outcomes. Fetal fraction was assessed as a continuous variable and as <10th percentile, corresponding to a fetal fraction <2.5%. Results: The cohort comprised 56,110 pregnancies. In the analysis of fetal fraction as a continuous variable, a decrease in fetal fraction was associated with increased risk of hypertensive disorders of pregnancy (adjusted odds ratio, 2.27 [95% confidence interval, 1.89–2.78]), small for gestational age neonates <10th percentile (adjusted odds ratio, 1.37 [1.28–1.45]) and <2.3rd percentile (adjusted odds ratio, 2.63 [1.96–3.57]), and spontaneous preterm birth from 24 to 37 weeks of gestation (adjusted odds ratio, 1.02 [1.01–1.03]). No association was found for fetal congenital anomalies (adjusted odds ratio, 1.02 [1.00–1.04]), stillbirth (adjusted odds ratio, 1.02 [0.96–1.08]), or neonatal death (adjusted odds ratio, 1.02 [0.96–1.08]). Similar associations were found for adverse pregnancy outcomes when fetal fraction was <10th percentile. Conclusion: In early pregnancy, a

Published
2023

11. Association between low fetal fraction in cell-free DNA screening and fetal chromosomal aberrations: A systematic review and meta-analysis

Author

MS Verloskunde, Epi Methoden Team 4, Cancer, JC onderzoeksprogramma Methodologie, Child Health, Circulatory Health, Becking, Ellis C, Schuit, Ewoud, van Baar de Knegt, Sophie M E, Sistermans, Erik A, Henneman, Lidewij, Bekker, Mireille N, Scheffer, Peter G, MS Verloskunde, Epi Methoden Team 4, Cancer, JC onderzoeksprogramma Methodologie, Child Health, Circulatory Health, Becking, Ellis C, Schuit, Ewoud, van Baar de Knegt, Sophie M E, Sistermans, Erik A, Henneman, Lidewij, Bekker, Mireille N, and Scheffer, Peter G

Published
2023

13. Variability in Fetal Fraction Estimation: Comparing Fetal Fractions Reported by Noninvasive Prenatal Testing Providers Globally

Author

Becking, Ellis C, primary, Linthorst, Jasper, additional, Patton, Simon, additional, Gutowska-Ding, Weronika, additional, Goodall, Rebecca, additional, Khawaja, Farrah, additional, Morgan, Fiona, additional, Deans, Zandra, additional, Chitty, Lyn S, additional, Bekker, Mireille N, additional, Scheffer, Peter G, additional, and Sistermans, Erik A, additional

Published
2022
Full Text
View/download PDF

22. Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study

Author

Alssema, Marjan, El-Harchaoui, Karim, Schindhelm, Roger K., Diamant, Michaela, Nijpels, Giel, Kostense, Piet J., Teerlink, Tom, Heine, Robert J., Dallinga-Thie, Geesje M., Kuivenhoven, Jan A., Dekker, Jacqueline M., and Scheffer, Peter G.

Published
2010
Full Text
View/download PDF

23. Low fetal fraction in cell-free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENT-2 study: analysis of a subcohort of the TRIDENT-2 study

Author

Becking, Ellis C., Wirjosoekarto, Soetinah A. M., Scheffer, Peter G., Huiskes, Julia V. M., Remmelink, Marinka J., Sistermans, Eril A., Bax, Caroline J., Weiss, Janneke M., Henneman, Lidewij, Bekker, Mireille N., Obstetrics and gynaecology, Human genetics, APH - Quality of Care, and Amsterdam Reproduction & Development (AR&D)

Abstract

Objectives: To assess the association between low fetal fraction (FF) in prenatal cell-free DNA (cfDNA) testing and adverse pregnancy outcomes. Methods: We conducted a retrospective cohort study of participants of the TRIDENT-2 study (Dutch nationwide government-supported study offering cfDNA screening for fetal aneuploidies) who received a failed test result due to low FF (

Published
2021
Full Text
View/download PDF

24. Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: A systematic review:A systematic review

Author

Scheffer, Peter G., Wirjosoekarto, Soetinah A. M., Becking, Ellis C., Weiss, Marjan M., Bax, Caroline J., Oepkes, Dick, Sistermans, Erik A., Henneman, Lidewij, and Bekker, Mireille N.

Abstract

Objective: Low fetal fraction (LFF) in prenatal cell-free DNA (cfDNA) testing is an important cause of test failure and no-call results. LFF might reflect early abnormal placentation and therefore be associated with adverse pregnancy outcome. Here, we review the available literature on the relationship between LFF in cfDNA testing and adverse pregnancy outcome. Method: A systematic literature search was conducted in MEDLINE and EMBASE up to November 1, 2020. Results: Five studies met the criteria for inclusion; all were retrospective observational cohort studies. The cohort sizes ranged from 370 to 6375 pregnancies, with all tests performed in the first trimester or early second trimester. A 4% cutoff for LFF was used in two studies, two studies used the 5th and 25th percentiles, respectively, and one study used a variety of cutoff values for LFF. LFF in prenatal cfDNA testing was observed to be associated with hypertensive disease of pregnancy, small for gestational age neonates, and preterm birth. Conflicting results were found regarding the association between LFF and gestational diabetes mellitus. Conclusions: LFF in cfDNA testing is associated with adverse pregnancy outcome,specifically pregnancy-related hypertensive disorders, preterm birth, and impaired fetal growth related to placental dysfunction. Since the available evidence is limited, a large prospective cohort study on the relationship between fetal fraction and pregnancy outcomes is needed.

Published
2021
Full Text
View/download PDF

27. Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: A systematic review

Author

MS Verloskunde, Child Health, Circulatory Health, Scheffer, Peter G., Wirjosoekarto, Soetinah A.M., Becking, Ellis C., Weiss, Marjan M., Bax, Caroline J., Oepkes, Dick, Sistermans, Erik A., Henneman, Lidewij, Bekker, Mireille N., MS Verloskunde, Child Health, Circulatory Health, Scheffer, Peter G., Wirjosoekarto, Soetinah A.M., Becking, Ellis C., Weiss, Marjan M., Bax, Caroline J., Oepkes, Dick, Sistermans, Erik A., Henneman, Lidewij, and Bekker, Mireille N.

Published
2021

28. Low fetal fraction in cell-free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENT-2 study

Author

MS Verloskunde, Urologie Onderzoek, Child Health, Circulatory Health, Becking, Ellis C., Wirjosoekarto, Soetinah A.M., Scheffer, Peter G., Huiskes, Julia V.M., Remmelink, Marinka J., Sistermans, Erik A., Bax, Caroline J., Weiss, Janneke M., Henneman, Lidewij, Bekker, Mireille N., MS Verloskunde, Urologie Onderzoek, Child Health, Circulatory Health, Becking, Ellis C., Wirjosoekarto, Soetinah A.M., Scheffer, Peter G., Huiskes, Julia V.M., Remmelink, Marinka J., Sistermans, Erik A., Bax, Caroline J., Weiss, Janneke M., Henneman, Lidewij, and Bekker, Mireille N.

Published
2021

39. Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study

Author

Nanayakkara, Prabath W. B., van Guldener, Coen, ter Wee, Piet M., Scheffer, Peter G., van Ittersum, Frans J., Twisk, Jos W., Teerlink, Tom, van Dorp, Wim, and Stehouwer, Coen D. A.

Published
2007

47. First‐Trimester Prediction Models Based on Maternal Characteristics for Adverse Pregnancy Outcomes: A Systematic Review and Meta‐Analysis.

Author

van Eekhout, Jacintha C. A., Becking, Ellis C., Scheffer, Peter G., Koutsoliakos, Ioannis, Bax, Caroline J., Henneman, Lidewij, Bekker, Mireille N., and Schuit, Ewoud

Subjects
*SMALL for gestational age, *FIRST trimester of pregnancy, *GESTATIONAL diabetes, *PREGNANCY outcomes, *PREMATURE labor
Abstract

Background Objectives Search Strategy Selection Criteria Data Collection and Analysis Main results Conclusions Early risk stratification can facilitate timely interventions for adverse pregnancy outcomes, including preeclampsia (PE), small‐for‐gestational‐age neonates (SGA), spontaneous preterm birth (sPTB) and gestational diabetes mellitus (GDM).To perform a systematic review and meta‐analysis of first‐trimester prediction models for adverse pregnancy outcomes.The PubMed database was searched until 6 June 2024.First‐trimester prediction models based on maternal characteristics were included. Articles reporting on prediction models that comprised biochemical or ultrasound markers were excluded.Two authors identified articles, extracted data and assessed risk of bias and applicability using PROBAST.A total of 77 articles were included, comprising 30 developed models for PE, 15 for SGA, 11 for sPTB and 35 for GDM. Discriminatory performance in terms of median area under the curve (AUC) of these models was 0.75 [IQR 0.69–0.78] for PE models, 0.62 [0.60–0.71] for SGA models of nulliparous women, 0.74 [0.72–0.74] for SGA models of multiparous women, 0.65 [0.61–0.67] for sPTB models of nulliparous women, 0.71 [0.68–0.74] for sPTB models of multiparous women and 0.71 [0.67–0.76] for GDM models. Internal validation was performed in 40/91 (43.9%) of the models. Model calibration was reported in 21/91 (23.1%) models. External validation was performed a total of 96 times in 45/91 (49.5%) of the models. High risk of bias was observed in 94.5% of the developed models and in 58.3% of the external validations.Multiple first‐trimester prediction models are available, but almost all suffer from high risk of bias, and internal and external validations were often not performed. Hence, methodological quality improvement and assessment of the clinical utility are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Hyperoxia does not affect oxygen delivery in healthy volunteers while causing a decrease in sublingual perfusion

Author

Smit, Bob, primary, Smulders, Yvo M., additional, Eringa, Etto C., additional, Gelissen, Harry P. M. M., additional, Girbes, Armand R. J., additional, de Grooth, Harm‐Jan S., additional, Schotman, Hans H. M., additional, Scheffer, Peter G., additional, Oudemans‐van Straaten, Heleen M., additional, and Spoelstra‐de Man, Angelique M. E., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results